Back to User profile » Dr Chih-Hung Hsu
Papers published by Dr Chih-Hung Hsu:
Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma [Corrigendum]
Chen CT, Chuang CH, Hsu CH, Shao YY
Journal of Hepatocellular Carcinoma 2026, 13:611160
Published Date: 27 March 2026
Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
Chen CT, Chuang CH, Hsu CH, Shao YY
Journal of Hepatocellular Carcinoma 2025, 12:2341-2349
Published Date: 15 October 2025
Treatment Outcomes of Systemic Therapies for Infiltrative Hepatocellular Carcinoma
Chen PY, Chang CK, Chen BB, Hsu CH, Cheng AL, Shao YY
Journal of Hepatocellular Carcinoma 2025, 12:1221-1229
Published Date: 23 June 2025
Changes in Posttreatment Spleen Volume Associated with Immunotherapy Outcomes for Advanced Hepatocellular Carcinoma
Chen BB, Liang PC, Shih TTF, Liu TH, Shen YC, Lu LC, Lin ZZ, Hsu C, Hsu CH, Cheng AL, Shao YY
Journal of Hepatocellular Carcinoma 2024, 11:1015-1029
Published Date: 5 June 2024
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma
Shen YC, Lee PC, Kuo YL, Wu WK, Chen CC, Lei CH, Yeh CP, Hsu C, Hsu CH, Lin ZZ, Shao YY, Lu LC, Liu TH, Chen CH, Wu MS, Huang YH, Cheng AL
Journal of Hepatocellular Carcinoma 2021, 8:809-822
Published Date: 24 July 2021
Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives
Lu LC, Chang CJ, Hsu CH
Journal of Hepatocellular Carcinoma 2019, 6:71-84
Published Date: 7 May 2019
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
Hsu CH, Shen YC, Shao YY, Hsu C, Cheng AL
Journal of Hepatocellular Carcinoma 2014, 1:85-99
Published Date: 12 June 2014